Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...
Fineline Cube
Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...
Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC
US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...
GSK and Abbott Announce Leadership Changes in Key Roles
Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON:...
Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation
US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3)...
QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., and Guangdong Hengjian Investment Holding...
Deepwise Information Integrates DeepSeek into Medical Data Platform
Deepwise Information, a leading artificial intelligence company in the medical field, has fully integrated its...
Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round
Weimai Qingtong Medical Technology (WEMT), a medical device company based in Wuxi, has completed a...
InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received approval from...
Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety
In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...
Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) announced that its mecobalamin product has...
Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn...
AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans
Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...
Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market
China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...